Fig. 1

Early improvement in CAP or HAP patients, by risk factors and causative pathogen. Top panel. Early improvement at Day 3 in patients with CAP, by risk factor (CE population). Middle panel. Early improvement at Day 4 in patients with HAP (excluding VAP) by risk factor (CE population). Lower panel. Early improvement in high-risk group patients by pathogen type (CE population). ^aThe comparator treatment was ceftriaxone ± linezolid in CAP patients and ceftazidime plus linezolid in HAP (excluding VAP) patients. ^bBetween treatment difference calculated as ceftobiprole minus comparator ^cTwo-sided 95% confidence interval is based on a normal approximation to the difference of the two proportions. Analyses were not conducted in bacteraemia high-risk groups as the number of CAP and HAP patients in both treatment arms was <20. Early clinical improvement is defined as improved or cured at Day 3 in patients with CAP, and improved or cured at Day 4 in patients with HAP (excluding VAP). Early clinical improvements were evaluated by the investigator, based on an assessment of symptoms using standardised criteria